Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
36 participants
INTERVENTIONAL
2016-12-31
2017-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products
NCT00875277
An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris
NCT01466478
A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris
NCT01347255
A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)
NCT02416258
LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris
NCT02132936
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LEO 90100 aerosol foam
LEO 90100 calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate) aerosol foam
Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.
LEO 90100 aerosol foam
Dermoval®/Dermovate®
Diprosone
Elocon
Locoid
LEO 90100 foam vehicle
Dermoval®/Dermovate®
Dermoval®/Dermovate® (clobetasol propionate 0.05%) cream
Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.
LEO 90100 aerosol foam
Dermoval®/Dermovate®
Diprosone
Elocon
Locoid
LEO 90100 foam vehicle
Diprosone®
Diprosone® betamethasone 0.5 mg/g (as dipropionate) ointment
Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.
LEO 90100 aerosol foam
Dermoval®/Dermovate®
Diprosone
Elocon
Locoid
LEO 90100 foam vehicle
Elocon®
Elocon® mometasone furoate 0.1% cream
Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.
LEO 90100 aerosol foam
Dermoval®/Dermovate®
Diprosone
Elocon
Locoid
LEO 90100 foam vehicle
Locoid®
Locoid® hydrocortisone-17-butyrate 0.1% ointment
Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.
LEO 90100 aerosol foam
Dermoval®/Dermovate®
Diprosone
Elocon
Locoid
LEO 90100 foam vehicle
LEO 90100 foam vehicle
LEO 90100 foam vehicle
Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.
LEO 90100 aerosol foam
Dermoval®/Dermovate®
Diprosone
Elocon
Locoid
LEO 90100 foam vehicle
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LEO 90100 aerosol foam
Dermoval®/Dermovate®
Diprosone
Elocon
Locoid
LEO 90100 foam vehicle
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects without signs of skin irritation/disease/disorders/symptoms or blemishes on test sites (e.g. erythema, dryness, roughness, scaling, scars, moles, sunburn).
Exclusion Criteria
* Female subjects who are breastfeeding.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LEO Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CPCAD
Nice, Cedex, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LP0053-1276
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.